Department of Internal Medicine III, University Hospital Olomouc, Czech Republic.
Neoplasma. 2010;57(1):8-14. doi: 10.4149/neo_2010_01_008.
We analyzed proliferative index of myeloma plasmocytes (PC-PI) in acohort of 217 patients with multiple myeloma (MM) treated with conventional chemotherapy and biological agents, thalidomide and bortezomib. In the whole group was adifference between overall survival (OS) favoring patients with PC-PI ven after 40 months (median overall survival 25 vs 10months, p= 0.015), whereas in the group treated with thalidomide and bortezomib was no difference, with medians over 39 months. Even patients with low PC-PI profited from the treatment with novel drugs. Presented results suggest that the treatment of MM with novel agents overcomes the prognostic significance of PC-PI and should be used in all MM patients.
myeloma -prognostication -proliferative index -biological therapy.
我们分析了 217 例多发性骨髓瘤（MM）患者的骨髓瘤浆细胞增殖指数（PC-PI），这些患者接受了常规化疗和生物制剂、沙利度胺和硼替佐米治疗。在整个组中，PC-PI 后总生存（OS）有差异，中位总生存时间为 25 个月比 10 个月（p=0.015），而在接受沙利度胺和硼替佐米治疗的组中则没有差异，中位生存时间超过 39 个月。即使是 PC-PI 低的患者也从新型药物治疗中获益。目前的结果表明，新型药物治疗 MM 可以克服 PC-PI 的预后意义，应在所有 MM 患者中使用。
骨髓瘤 - 预后 - 增殖指数 - 生物治疗。
